Patent application number | Description | Published |
20080226639 | Heparin Binding Peptide - The invention relates to new peptide fragments capable of stimulating neurite outgrowth, stimulating of cell survival, stimulating neural plasticity associated with memory and learning, and modulating cell motility. The biological activity of the peptide fragments is associated with their capability of binding and activating a neurotrophin receptor of the Trk family. The peptide fragments of the invention comprise an amino acid motif which is essential for binding and activating a neurotrophin receptor of the Trk family. The invention also concerns pharmaceutical compositions comprising the compounds and uses thereof for prevention and/or treatment of conditions and/or diseases, wherein neurotrophing, Tkr receptors and/or NCAM play an important role, and wherein stimulating of neurite outgrowth, cell survival, neural plasticity associated with memory and learning, and/or modulating cell motility is beneficial for treatment. | 09-18-2008 |
20080249004 | Method of Modulating Cell Survival, Differentiation and/or Synaptic Plasticity - The present invention relates to a method of modulating differentiation, adhesion and/or survival of the neural cell adhesion molecule (NCAM) presenting cells by providing compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM. The invention provides candidate compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM by using methods for screening and testing described in the application. The invention further relates to pharmaceutical compositions comprising compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM and to use of the pharmaceutical compositions and compounds for the modulation of differentiation, adhesion and/or survival of NCAM presenting cells. | 10-09-2008 |
20090202554 | METHOD OF MODULATION OF INTERACTION BETWEEN RECEPTOR AND LIGAND - The present invention relates to a method for modulating the interaction between at least two proteins, wherein at least one of the two proteins is a functional cell-surface receptor and the other protein is the receptor ligand. The invention features a binding site of said functional cell-surface receptor on the receptor ligand and discloses a series of amino acid sequences, which are part of the structure of said binding site and/or involved in the interaction between the receptor and the ligand. Moreover, the present invention features methods for molecular design and screening of a candidate compound capable of modulating the interaction between the functional cell-surface receptor and receptor ligand through the described binding site, and provides a screening assay for identification of such a compound. The invention further describes an antibody capable of binding to the above binding site and/or to an epitope comprising an amino acid sequence essential for executing the receptor ligand interaction through said binding site. The invention also concerns a variety of uses of the disclosed methods, peptide sequences and antibodies. The invention in preferred embodiments concerns the binding site of the fibroblast growth factor receptor (FGFR) on FGFR ligands, compounds capable of modulating the receptor ligand interaction through sa d binding site, and antibody capable of recognition of said binding site. | 08-13-2009 |
20090305951 | COMPOUNDS CAPABLE OF AFFECTING DIFFERENTIATION, PROLIFERATION, REGENERATION, PLASTICITY AND SURVIVAL CELLS - The present invention relates to a compound comprising the third Immunoglobulin (Ig3) module, and/or the fourth Immunoglobulin (Ig4) module, and/or the fifth immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, capable of interacting with an Fibroblast Growth Factor (FGF) receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1, and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to a pharmaceutical composition comprising said compound, a process of producing a pharmaceutical composition and the use of said compound. | 12-10-2009 |
20100166759 | Metallothionein-Derived Peptide Fragments - The present invention relates to neural cell survival, differentiation and proliferation promoting peptide fragments derived from metallothioneins (MT), pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of diseases and conditions where the effects of stimulating neural cell proliferation, differentiation and/or survival, and/or stimulating neural plasticity associated with learning and memory are beneficial for treatment. | 07-01-2010 |
20110098225 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLs) - The present invention relates to novel compounds comprising at most 13 contiguous amino acid residues derived from the fibronectin type 3,I1 module of neural cell adhesion molecule (NCAM), or a variant or fragment thereof, capable of interacting with an FGFR and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to the use of said compounds for production of a medicament for treatment of conditions and diseases, wherein NCAM and/or FGFR play a prominent role. | 04-28-2011 |
20110300148 | IL-4-DERIVED PEPTIDES FOR MODULATION OF THE CHRONIC INFLAMMATORY RESPONSE AND TREATMENT OF AUTOIMMUNE DISEASES - The present invention relates to small peptides derived from a cytokine, interleukin-4 (IL-4), capable of binding to the IL-4 receptors and inhibiting macrophage activation, and thereby preventing the onset of inflammatory response. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein IL-4 plays a prominent role. | 12-08-2011 |
20120141451 | FIBROBLAST GROWTH FACTOR RECEPTOR-DERIVED PEPTIDES BINDING TO NCAM - The present invention relates to the use of peptides that are capable of binding to, and modulating the activity of NCAM. The peptides are peptide fragments of FGFRs. They are derived from two distinct binding sites for binding of the immunoglobulin-like module 2 of FGFR to NCAM F3 modules 1-2. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein NCAM and/or FGFRs play a prominent role. | 06-07-2012 |
20140073556 | Antagonists of the Interleukin-1 Receptor - The present invention discloses novel peptides derived from the IL-1 receptor antagonist protein (IL1 RA), capable of binding to the cell surface IL-1 receptor 1 (IL1 R1) and interfere with the binding of IL-1 to IL1 R1. This binding thus effectively antagonises the inflammatory effects of IL-1, such as by reducing TNF-alpha secretion from macrophages. This is of potential use as an anti-inflammatory factor throughout the human body, including the central nervous system. The use of said peptides as anti-inflammatory agents for treatment of pathological conditions wherein IL-1 plays a prominent role, such as inflammatory conditions of the body and the central nervous system, is thus an aspect of the present invention. | 03-13-2014 |
20140179614 | Metallothionein-Derived Peptide Fragments - The present invention relates to neural cell survival, differentiation and proliferation promoting peptide fragments derived from metallothioneins (MT), pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of diseases and conditions where the effects of stimulating neural cell proliferation, differentiation and/or survival, and/or stimulating neural plasticity associated with learning and memory are beneficial for treatment. | 06-26-2014 |
20140234294 | Fibroblast Growth Factor Receptor-Derived Peptides Binding to NCAM - The present invention relates to the use of peptides that are capable of binding to, and modulating the activity of NCAM. The peptides are peptide fragments of FGFRs. They are derived from two distinct binding sites for binding of the immunoglobulin-like module 2 of FGFR to NCAM F3 modules 1-2. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein NCAM and/or FGFRs play a prominent role. | 08-21-2014 |